The STAT News report captures surface-level confusion from the American College of Physicians' recent shift to age-50 biennial screening for average-risk women, yet overlooks how guideline bodies weigh outdated randomized controlled trials differently. The 2024 USPSTF update, drawing from meta-analyses of trials like the Swedish Two-County Study (n>130,000, RCT design) and Canadian National Breast Screening Study (n=89,000, criticized for poor mammography quality and contamination), favors starting at 40 despite modest mortality reductions of 15-20% offset by overdiagnosis rates up to 22% in observational cohorts. This clashes with ACS modeling emphasizing incidence spikes at 45, but both undervalue modern adjuncts like tomosynthesis shown in a 2023 JAMA RCT (n=150,000) to cut false positives by 15%. Dense breast notification laws, affecting 40% of women per ACR data, amplify harms without proven outcome gains in prospective studies. Esserman's risk-stratified trials highlight the core gap: absent integration of polygenic scores and lifestyle factors, public health messaging fails women at intermediate risk, perpetuating disparities seen in SEER registry trends of rising diagnoses.